Although the act would not prohibit manufacturers from increasing prices, it could change the pricing landscape. Here’s why.
Managed Healthcare Executive asked key opinion leaders their thoughts on the drug rebate controversy. Here’s what they said.
A 51-year-old female patient has been taking Forteo (teriparatide) for osteoporosis for the past year. Her insurance company notifies her that the drug is no longer on its formulary.
When it comes to promising areas in the treatment of lymphoma and other blood cancers, gene therapy may be at the top of the list. Here’s why.
Are recent pharma price drops just a response to political pressure or will the momentum last? Managed Healthcare Executive asked industry experts, and here’s what they said.
Amazon captured the industry’s attention once again when it announced it is acquiring online pharmacy PillPack for a reported $1 billion. Here’s how experts say it will affect managed care.
Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.
Prices of more than 20% of generic drugs increased more than 100% between 2010 and 2015.
Recommendations focus on ways to prevent opioid misuse and reduce risk of addiction.
FDA’s plan to evaluate gene therapies’ impact on surrogate end points is amping up concerns among payers. Here’s why